J&J's Van Hoof Talks About Expanding Vaccines Development
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.
You may also be interested in...
Keeping Track: Ofev Snags SSc-ILD Indication, Accelerated Approval Reviews For Veverimer And Voxelotor, J&J Gets Its First Vaccine BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Janssen R&D Unveils Three New Research Platforms
With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
J&J follows its brethren into vaccines, and Crucell lands a big-pharma partner in the wake of its failed deal with Wyeth.